Overlook Medical Center

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Stroke4 trials
• Childhood cancers2 trials
• Coronary artery disease2 trials
• Aortic stenosis1 trial
• Atrial fibrillation1 trial
• Bladder cancer1 trial
• Chronic kidney disease1 trial
• Colorectal cancer1 trial
• Liver and biliary tract cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• and 5 more

Phase

• Phase 38 trials
• Phase 25 trials
• Early phase 11 trial

Status

• Recruiting7 trials
• Completed5 trials
• Active, not recruiting3 trials
• Not yet recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals3 trials
• Humacyte, Inc.2 trials
• Agenus Inc.1 trial
• Atlantic Health System1 trial
• Daiichi Sankyo1 trial
• and 8 more

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Not yet recruiting

  A Novel Method for Determination of Thromboembolic Stroke Origin

  NCT06961604· Early phase 1· Atlantic Health System· Source

  Contact: James Cassuto, MD, PhD

• Recruiting

  Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  NCT06418204· Wake Forest University Health Sciences· Source

  Contact: Raimonda Goldman (principal investigator)

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

  NCT06538038· PrECOG, LLC.· Source

• Recruiting

  A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

  NCT05646381· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Rosmery Montesino

• Recruiting

  Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

  NCT05950945· Phase 3· Daiichi Sankyo· Source

  Contact: Study Coordinator

• Recruiting

  A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  NCT05503797· Phase 2· Fore Biotherapeutics· Source

  Contact: Jessica Rine

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Jazz Pharmaceuticals· Source

  Contact: Clinical Trial Disclosure & Transparency

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Recruiting

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

  NCT03907046· Phase 3· Yale University· Source

  Contact: Marianna Atiya, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Stroke2 recruiting
• Aortic stenosis1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting
• Thyroid cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

  NCT05630183· Phase 2· Agenus Inc.· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

  NCT03183245· Phase 3· Humacyte, Inc.· Source

• Completed

  Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

  NCT02887859· Phase 2· Humacyte, Inc.· Source

• Completed

  Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

  NCT02486718· Phase 3· Hoffmann-La Roche· Source